HOOKIPA to sell HB-400/HB-500 assets to Gilead for up to $10M; board approves dissolution

HOOKIPA Pharma Inc.

Gilead to acquire HB-400 and HB-500 assets for up to $10M in cash; $3M at closing, up to $7M in transfer completion payments.
Board approved dissolution of HOOKIPA; filing of Certificate of Dissolution expected after Transfer Plan completion.
Asset sale and dissolution require stockholder approval; proxy statement to be filed for special meeting.
CEO Malte Peters receives severance, accelerated equity vesting, and a Special Dissolution Success Bonus up to €482,591.
Collaboration Agreement and Stock Purchase Agreement with Gilead will terminate at closing.

item 1.01 item 1.02 item 5.02 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.